DIBENZYLINE
Pronunciation: fen-ox-ee-BEN-za-meen

What it isIrreversible non-selective alpha antagonist; preoperative blockade in phaeochromocytoma.
Why this oneIrreversible blockade cannot be overcome by a catecholamine surge, which is exactly what is needed during tumor handling.
What limits itReflex tachycardia and profound orthostasis; a beta blocker must not be started first. The effect persists for days after stopping.
Animated chart of estimated U.S. prescriptions per year, Antihypertensives (1953–2026). Phenoxybenzamine enters in 1953 (estimated).
Principal riskReflex tachycardia and profound orthostasis
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Pheochromocytoma (control of hypertension and sweating episodes) | Adults | 10 mg BID | 20–40 mg BID–TID (titrated to BP control) | Undefined |
Titration Every other day
Renal Undefined
Hepatic Undefined
Long-term use not recommended (carcinogenicity). Add a beta-blocker if tachycardia is excessive.
Available strengths
Pregnancy No adequate animal reproduction studies; unknown fetal risk — use only if clearly needed.
Lactation Unknown whether excreted in milk; discontinue nursing or drug.
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 10 mg | cap | 60 BID | offered |
Generic entry2012
Open Phenoxybenzamine in the interactive console ↗